Page last updated: 2024-12-07
isf 2405
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
ISF 2405: metabolite of cadralazine; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 129853 |
| SCHEMBL ID | 10844198 |
| MeSH ID | M0156907 |
Synonyms (16)
| Synonym |
|---|
| isf 2405 |
| 70887-18-2 |
| 1-[ethyl-(6-hydrazinylpyridazin-3-yl)amino]propan-2-ol |
| cadralazine m |
| isf-2405 |
| cgp 22639 |
| 6-(ethyl-(2-hydroxypropyl)amino)-3-hydrazinopyridazine |
| 3(2h)-pyridazinone, 6-(ethyl(2-hydroxypropyl)amino)-, hydrazone |
| 113341-59-6 |
| OWMCFGLDBWRVDZ-UHFFFAOYSA-N |
| 3-[ethyl(2-hydroxypropyl)amino]-6-hydrazinopyridazine |
| SCHEMBL10844198 |
| 1-[ethyl(6-hydrazinylidene-1,6-dihydropyridazin-3-yl)amino]propan-2-ol |
| DTXSID40921043 |
| 1-(ethyl(6-hydrazono-1,6-dihydropyridazin-3-yl)amino)propan-2-ol |
| STARBLD0008452 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " There were no differences between the two groups in AUC and Cmax values of cadralazine and apparent metabolite, the latter defined as the sum of the free and conjugated hydrazinopyridazine." | ( Influence of acetylator status on the haemodynamic effects and pharmacokinetics of cadralazine in healthy subjects. Brunel, P; Guyene, TT; Imhof, P; Lecaillon, JB; Ménard, J, 1990) | 0.28 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (42.86) | 18.7374 |
| 1990's | 4 (57.14) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.11
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.11) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (11.11%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (88.89%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||